NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology
NETRIS Pharma attending the Bio International Convention in Boston (June 5-8, 2023)
NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137
As the world pioneer and leader biopharmaceutical company targeting netrin-1 and ligands of Dependence Receptors, NETRIS Pharma has built and is periodically reinforcing a unique portfolio of worldwide exclusive rights and patents on all key elements of its approach.
NETRIS Pharma has grown from inception with the full support of Research, Clinical and Corporate Partners.